In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Clinical and economic outcome of telemonitoring versus usual care among patients with severe chronic heart failure

Session Remote patient monitoring: better care at lower cost. Is this a dream?

Speaker Paul Dendale

Event : ESC Congress 2015

  • Topic : e-cardiology / digital health, public health, health economics, research methodology
  • Sub-topic : Remote Patient Monitoring and Telemedicine
  • Session type : Advances in Science

Authors : P Dendale (Hasselt,BE), I Cleemput (Brussels,BE), R Hoffmann (Hasselt,BE), D Vandijck (Hasselt,BE)

Authors:
P. Dendale1 , I. Cleemput2 , R. Hoffmann1 , D. Vandijck1 , 1Hasselt University, Faculty of Medicine and Life Sciences - Hasselt - Belgium , 2Belgian Health Care Knowledge Centre (KCE) - Brussels - Belgium ,

Citation:
European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 3

Background: Chronic heart failure (CHF) is a common, serious, and costly disease whose clinical course is often characterized by recurrent hospitalizations due to fluid overload and/or worsening of renal function. Frequent (i.e. almost real-time) adjustments of treatment are needed to lower morbidity, mortality, and healthcare costs.

Purpose: To assess whether follow-up of CHF patients using telemonitoring (TM) vs. usual care (UC) impacts patient and economic outcome.

Methods: One hundred and sixty CHF patients (mean age 76±10 years, 104 males, mean left ventricular ejection fraction 35±15%) were block randomized by sealed envelopes and assigned to 6 months of intense follow-up facilitated by TM or UC. The TM group measured body weight, blood pressure, and heart rate on a daily basis with electronic devices that transferred the data automatically to an online database. Email alerts were sent to the patients' general practitioner as well as to the heart failure centre to proactively intervene when pre-defined limits were exceeded. Individual healthcare costs were obtained from the Belgian healthcare expenditures database.

Results: All-cause mortality was significantly lower in the TM group than in the UC group (5% vs. 17.5%, P=0.01). The total number of follow-up days lost to hospitalization, dialysis, or death was significantly lower in the TM group as compared with the UC group (13 vs. 30 days, P=0.02). The number of hospitalizations for heart failure per patient showed a non-significant trend in favor of TM (0.24 vs. 0.42 hospitalizations/patient, P=0.06). Although the total drug and healthcare expenditures per patient/month were higher in the UC group than in the TM group (€678.28±1,246.02 vs. €477.72±1,239.04 and €5,392.76±8,084.40 vs. €4,327.30±10,021.00), the differences were not statistically significant.

Conclusion: Although the use of TM in a cohort of patients with severe chronic heart failure positively impacts clinical outcome, it does not reduce healthcare costs. A large randomized trial is, however, needed to confirm these findings.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are